JPRN-UMIN000010470已完成1 期
Evaluation of the Feasible dose of Lenalidomide as maintenance therapy after Allogeneic hematopoietic stem cell Transplantation for multiple myeloma - E-FLAT study
Division of Hematology, Saitama Medical Center, Jichi Medical University0 个研究点目标入组 9 人开始时间: 2013年4月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients with poorly controlled in spite of the continuous use of insulin (2) Patients with poorly controlled hypertension (3) Patients with poorly controlled active infection (4) Patients with coexistence of malignancy (5) Patients who are or may be pregnant or are nursing (6) Patients with serious mental disorder (7) Patients with HBs antigen or HBe antigen positive (8) Patients with HIV antibody positive (9) Patients who are allergic to lenalidomide or thalidomide (10) Patients with active acute or chronic GVHD (11) Patients with platelet count < 30,000/uL or neutrophil count < 1,000/u
研究者
相似试验
进行中（未招募）
不适用
Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation - Revlimid as Maintenance in MMMultiple Myeloma patients who received allogeneic stem cell transplantation (100 to 180 days ago)MedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2007-003784-42-DEniversity Medical Center Hamburg-Eppendorf
进行中（未招募）
不适用
Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002POEMS SYNDROMEMedDRA version: 9.1Level: SOCClassification code 10029205EUCTR2008-003202-33-ITISTITUTO CLINICO HUMANITAS
进行中（未招募）
不适用
A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEXAL amyloidosisEUCTR2008-001405-41-DEGMIHO mbH
已完成
不适用
Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentratiomultiple myelomaJPRN-UMIN000022257Japan Community Health care Organization Kyoto Kuramaguchi Medical Center30
撤回
2 期
enalidomide with epigenetic therapy in relapsed or refractory Acute Myeloid Leukaemia (AML)-Phase IIrelapsed and refractory acute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12612000312842Australasian Leukaemia and Lymphoma Group120